Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. filed a Form 3 naming Nerissa Kreher as a reporting person in the capacity of a director. The filing’s transaction summary shows no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction counts and share amounts listed as zero.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Net buy/sell direction: neutral +1 more

4 metrics

Buy transactions reported 0 transactionSummary buyCount

Sell transactions reported 0 transactionSummary sellCount

Net buy/sell direction neutral transactionSummary netBuySellDirection

Holding entries 0 transactionSummary holdingEntries

Key Terms

Form 3, reporting person, transaction summary

3 terms

Form 3 regulatory

"Xeris Biopharma Holdings, Inc. filed a Form 3 naming Nerissa Kreher"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

"filed a Form 3 naming Nerissa Kreher as a reporting person in the capacity of a director"

transaction summary financial

"The filing’s transaction summary shows no reported buying, selling, acquiring, disposing, or other share transactions"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/02/2026 - 06:00 PM Accepted by SEC EDGAR 07/02/2026 - 05:59 PM Learn about SEC filing dates

FAQ

What does the XERS Form 3 filing for Nerissa Kreher show?

The Form 3 identifies Nerissa Kreher as a reporting person and director of Xeris Biopharma Holdings, Inc. It shows no reported share transactions, with all buy, sell, acquire, dispose, and other transaction counts and share amounts listed as zero in the transaction summary.

Are any share purchases or sales reported for XERS director Nerissa Kreher?

No share purchases or sales are reported. The transaction summary lists buyCount and sellCount as zero, with buyShares and sellShares also at zero, indicating no reported buying or selling activity for Nerissa Kreher in this Form 3 filing data.

Does the XERS Form 3 show any derivative exercises or restructurings?

No derivative activity or restructurings are shown. The transaction summary records exerciseCount, derivativeTransactionCount, and restructuringCount as zero, and the derivativeSummary is empty, indicating no reported options, warrants, or restructuring-related transactions for this reporting person in the filing data provided.

Is Nerissa Kreher a ten percent owner of Xeris Biopharma (XERS) in this filing?

The filing data indicates that is_ten_percent_owner is set to 0 for reporting person Nerissa Kreher. This means she is identified as a director but not as a ten percent owner in the structured information supplied for this Form 3.

Does the XERS Form 3 list any current holdings for Nerissa Kreher?

The transaction summary shows holdingEntries equal to zero and the derivativeSummary field is empty. Within this structured data, no specific holdings entries or derivative positions are provided for Nerissa Kreher in connection with this Form 3 filing snapshot.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

KREHER NERISSA

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

	/s/ Beth Hecht, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)